12.70
Korro Bio Inc stock is traded at $12.70, with a volume of 788.71K.
It is up +4.35% in the last 24 hours and up +3.00% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
See More
Previous Close:
$12.17
Open:
$12.09
24h Volume:
788.71K
Relative Volume:
4.40
Market Cap:
$183.17M
Revenue:
$6.39M
Net Income/Loss:
$-117.26M
P/E Ratio:
-1.0176
EPS:
-12.4807
Net Cash Flow:
$-79.08M
1W Performance:
-2.23%
1M Performance:
+3.00%
6M Performance:
+56.40%
1Y Performance:
+2.92%
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
KRRO
Korro Bio Inc
|
12.70 | 183.17M | 6.39M | -117.26M | -79.08M | -12.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-29-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-29-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-29-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-28-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-28-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio, Inc. (KRRO) soars 17.6%: Is further upside left in the stock? - MSN
Korro Bio, Inc. Actuals & Estimates (NASDAQ:KRRO) - TradingView
KRRO Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Korro Bio Inc For: 24 June By Investing.com - Investing.com Nigeria
Korro Bio Insider Sold Shares Worth $2,458,582, According to a Recent SEC Filing - marketscreener.com
Korro Bio director Jean Francois Formela sells $2.45m in shares - Investing.com
Form 144 Korro Bio For: 24 June By Investing.com - Investing.com Canada
Atlas Venture (KRRO) sells 101,579 shares on 06/23/2026, multiple Form 144 entries - Stock Titan
Korro Bio Inc (KRRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 144 Korro Bio For: 23 June By Investing.com - Investing.com South Africa
Form 144 Korro Bio For: 22 June By Investing.com - Investing.com Australia
Atlas Venture sells KRRO (KRRO) stock — 2,441 and 419 shares reported - Stock Titan
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock? - Yahoo Finance
Korro Bio COO Chappell sells $34,309 in company stock By Investing.com - Investing.com South Africa
Korro Bio COO Chappell sells $34,309 in company stock - Investing.com UK
Korro Bio Inc (KRRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Korro Bio Inc (KRRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Korro Bio Inc (KRRO) Institutional Confidence - TradingKey
Korro Bio Inc (KRRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Korro Bio Inc (KRRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Korro Bio Inc (KRRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Korro Bio Inc (KRRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Korro Bio Inc (KRRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Korro Bio (KRRO) CSO sells 3,418 shares to cover RSU taxes - Stock Titan
Korro Bio: RNA Editor Plots Way Back After AATD Study FailI'm Holding (NASDAQ:KRRO) - Seeking Alpha
KRRO Q1 2026 Earnings: Narrowed Loss Surprises to the Upside, Shares RallyEarnings Surprise Stocks - newsline.com
KORRO BIO INC (KRRO) Stock Chart - ChartMill
Korro Bio Stockholders Approve Directors, Pay and Auditor - The Globe and Mail
Korro Bio (KRRO) director Ali Behbahani receives 14,677 stock options grant - Stock Titan
Korro Bio (KRRO) director receives 14,677 stock options at $10.59 strike - Stock Titan
Korro Bio (KRRO) director Nessan Bermingham receives 14,677 stock options at $10.59 - Stock Titan
Korro Bio (KRRO) director awarded 14,677 stock options at $10.59 strike price - Stock Titan
Director at Korro Bio (NASDAQ: KRRO) awarded stock options for 14,677 shares - Stock Titan
Korro Bio (NASDAQ: KRRO) director receives 14,677 stock options grant - Stock Titan
What makes Korro Bio, Inc. (KRRO) a new buy stock - MSN
Korro Bio (NASDAQ: KRRO) investors back directors, pay and auditor - Stock Titan
One Korro Bio Insider Raised Stake By 19% In Previous Year - Yahoo Finance
KRRO Q1 2026 Earnings: Narrower-than-expected loss drives positive surprise despite revenue absencePerformance Review - newsline.com
KRRO Q1 2026 Earnings: EPS Beat But Stock Declines Amid No RevenueAnnual Report - newsline.com
KRRO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue PhaseManagement Tone Analysis - newsline.com
Korro Bio CEO Ram Aiyar sells $196,672 in company stock By Investing.com - Investing.com Nigeria
Korro Bio CEO Ram Aiyar sells $196,672 in company stock - Investing.com
Korro Bio director sells $39,897 in common stock By Investing.com - Investing.com Canada
Korro Bio director sells $39,897 in common stock - Investing.com
Korro Bio Inc. (KRRO) Faces Selling Pressure as Shares Retreat 3.21%Bear Pennant - The Legal Advocate
KRRO Q1 2026 Earnings: EPS Beat by 10.05% as Biotech Advances PipelineNext Quarter Guidance - The Legal Advocate
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Korro Bio Inc Stock (KRRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FORMELA JEAN FRANCOIS | Director |
Jun 24 '26 |
Sale |
14.61 |
48,438 |
707,491 |
169,556 |
| FORMELA JEAN FRANCOIS | Director |
Jun 22 '26 |
Sale |
13.95 |
3,962 |
55,270 |
194,075 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):